Type of security: Stock
Sector: Consumer Durables
Industry: Specialty Chemicals
Market Capitalization: 207.57 M
The data is delayed by 15 minutes.
Description: Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. Its lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. The company is also developing FMX101 to treat rosacea; and FDX104 to treat chemotherapy-induced rashes, as well as early-stage foam formulations of various drugs for the treatment of dermatological indications, including antibacterial drugs, antifungal drugs, corticosteroids, and immunomodulators. Foamix Pharmaceuticals Ltd. has development and license agreements Bayer AG, Merz Pharmaceuticals, LLC, Actavis plc, Prestium Pharma, Inc. and Arkin Holdings Ltd., and others. It has operations in the United States, Germany, and Israel. The company was founded in 2003 and is headquartered in Rehovot, Israel.
|Shares Outstanding||30.66 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||ROE||ROI|
|Current Ratio||Quick Ratio||Long Term Debt/Equity||Debt Ratio|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||250 K||Cash From Investing Activities||-31.18 M||Cash From Operating Activities||-1.91 M||Gross Profit||420 K|
|Net Profit||-3.08 M||Operating Profit||-3.07 M||Total Assets||49.82 M||Total Current Assets||42.28 M|
|Total Current Liabilities||3.29 M||Total Debt||540 K||Total Liabilities||3.66 M||Total Revenue||450 K|
|High 52 week||6.96||Low 52 week||3.33||Last close||3.69||Last change||1.37%|
|RSI||39.51||Average true range||0.18||Beta||0.9||Volume||52.12 K|
|Simple moving average 20 days||-1.39%||Simple moving average 50 days||-2.46%||Simple moving average 200 days||-24.87%|
|Performance Week||4.83%||Performance Month||-4.65%||Performance Quart||-16.7%||Performance Half||-35.94%|
|Performance Year||-43.84%||Performance Year-to-date||2.79%||Volatility daily||2.22%||Volatility weekly||4.96%|
|Volatility monthly||10.17%||Volatility yearly||35.23%||Relative Volume||159.06%||Average Volume||466.6 K|
|New High||0.82%||New Low|
2019-03-08 08:00:00 | Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019
2019-03-01 14:01:35 | Edited Transcript of FOMX earnings conference call or presentation 1-Mar-19 1:30pm GMT
2019-02-28 16:01:00 | Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update
2019-02-27 11:50:04 | How Many Insiders Bought Foamix Pharmaceuticals Ltd. NASDAQ:FOMX Shares?
2019-02-21 10:31:03 | Will Foamix FOMX Report Negative Earnings Next Week? What You Should Know
2019-01-23 08:00:00 | Foamix Announces Appointment of Sharon Barbari to Board of Directors
2019-01-22 11:38:35 | Are Foamix Pharmaceuticals Ltd.’s NASDAQ:FOMX Interest Costs Too High?
2018-12-16 22:16:18 | Is Foamix Pharmaceuticals Ltd FOMX A Good Stock To Buy?
2018-11-27 08:00:00 | Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
2018-11-19 08:00:00 | Foamix Announces Appointment of Anthony Bruno to Board of Directors
2018-11-13 07:55:00 | Recent Analysis Shows WPX Energy, Verizon Communications, Innovative Industrial Properties, Foamix Pharmaceuticals, O2Micro International, and Investment Technology Group Market Influences — Renewed Outlook, Key Drivers of Growth
2018-11-08 21:17:00 | Edited Transcript of FOMX earnings conference call or presentation 8-Nov-18 1:30pm GMT
2018-11-07 19:50:12 | Foamix FOMX Reports Q3 Loss, Lags Revenue Estimates
2018-11-07 16:05:00 | Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update
2018-11-07 06:00:01 | Foamix's treatment for common skin condition meets late-stage trial goals
2018-10-29 08:49:12 | Implied Volatility Surging for Foamix FOMX Stock Options
2018-10-22 12:26:04 | Does Foamix Pharmaceuticals Ltd NASDAQ:FOMX Have A High Beta?
2018-09-13 19:06:02 | Foamix Announces Pricing of its Follow-on Offering of Ordinary Shares
2018-09-12 16:31:58 | Foamix Announces Proposed Follow-on Offering of Ordinary Shares
2018-09-12 14:15:00 | Cannabis and Biotech Stock that could Explode
2018-09-12 09:58:01 | Foamix's Acne Candidate Succeeds in Study, Shares Rally
2018-09-12 08:34:00 | Foamix stock surges 30% on positive late-stage results for acne medication
2018-09-12 08:30:00 | Foamix's stock rockets after successful trial results for acne treatment
2018-09-11 17:39:53 | Foamix acne drug meets main goals in late-stage trial, shares surge
2018-09-07 11:54:26 | Did An Insider Sell Their Shares In Foamix Pharmaceuticals Ltd NASDAQ:FOMX?
2018-08-21 08:39:12 | Implied Volatility Surging for Foamix Pharmaceuticals FOMX Stock Options
2018-08-08 19:40:11 | Foamix FOMX Reports Q2 Loss, Lags Revenue Estimates
2018-08-08 18:37:33 | Foamix: 2Q Earnings Snapshot
2018-08-08 16:01:00 | Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate Update
2018-08-01 08:00:00 | Foamix Pharmaceuticals to Announce Second Quarter Financial Results on August 8
2018-06-14 08:00:00 | Foamix Pharmaceuticals to Participate in the Cantor Dermatology & Aesthetics Summit
2018-06-13 08:12:56 | Why Galmed Pharmaceuticals Stock Rose 151% on June 12
2018-05-22 12:02:17 | May Best Growth Stocks